Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Yu, Jian ^a   Zhang, Hongyu ^a   Gu, Jun ^a   Lin, Song ^b   Li, Junhua ^b   Lu, Wei ^c   Wang, Yifei ^c   Zhu, Jingde ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANDROGEN RECEPTOR; APC PROTEIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BRCA1 PROTEIN; CADHERIN; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEATH ASSOCIATED PROTEIN KINASE; DNA; ERYTHROPOIETIN; INTERFERON REGULATORY FACTOR 7; MELANOMA ANTIGEN 1; METALLOTHIONEIN I; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYOD1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN P14ARF; PROTEIN P15; PROTEIN P16INK4A; PROTEIN P57; PROTEIN P73; PROTEOCHONDROITIN SULFATE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOBLASTOMA PROTEIN; SURVIVIN; UVOMORULIN; VON HIPPEL LINDAU PROTEIN; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CDH16 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA BINDING PROTEIN; DRUG DERIVATIVE; MAGEA1 PROTEIN, HUMAN; MELANOMA ANTIGEN; NUCLEAR PROTEIN; RASSF1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; ASSAY; ASTROCYTOMA; CANCER CELL CULTURE; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE INACTIVATION; GENE INDUCTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; SCHOOL CHILD; SEQUENCE ANALYSIS; SEX DIFFERENCE; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION; BRAIN TUMOR; CHILD; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; GLIOMA; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; ANTIGENS, NEOPLASM; ASTROCYTOMA; AZACITIDINE; BRAIN NEOPLASMS; CADHERINS; CARCINOMA, HEPATOCELLULAR; CHILD; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; SEX FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 13144290928     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-65     Document Type: Article

References (69)

1. Kleihues P, Cavenee W: Astrocytic tumours. In: Pathology & Genetics Tumours of the Nervous System Edited by: Kleihues P, Cavenee W. Lyon: IARC Press; 2000:9-54.
2. Cancer Incidence and Mortality in China, 1993-1997 (Selected Cities and Counties). 1st edition. Beijing: China Publishing House of Medical Sciences and Technologies; 1998.
3. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313(5998):144-147.
4. Hegi ME, zur Hausen A, Ruedi D, Malin G, Kleihues P: Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 1997, 73(1):57-63.
5. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000, 60(2):417-424.
6. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13(5):1065-1072.
7. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K: Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1991, 6(8):1313-1318.
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947.
9. Jones PA: Epigenetics in carcinogenesis and cancer prevention. Ann N Y Acad Sci 2003, 983:213-219.
10. Feninberg A: Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 2001, 98(2):392-394.
11. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300(5618):455.
12. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R: Induction of tumors in mice by genomic hypomethylation. Science 2003, 300(5618 ):489-492.
13. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395(6697):89-93.
14. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB, Herman JG: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001, 10(26):3001-3007.
15. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001, 61(1): 49-255.
16. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D: Promoter hypermethylation patterns of p 16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001, 61(3):939-942.
17. Foster SA, Wong DJ, Barrett MT, Galloway DA: Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998, 18(4):1793-1801.
18. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002, 2(1):29.
19. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP: Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002, 62(22):6442-6446.
20. Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, Kim HY, Lee YS, Kang GH, Jeoung DI: Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun 2003, 307(1):52-63.
21. Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, Leng XS, Chen WF: Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 2002, 86(1):110-116.
22. Suyama T, Ohashi H, Nagai H, Hatano S, Asano H, Murate T, Saito H, Kinoshita T: The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. Leuk Res 2002, 26(12):1113-1118.
23. Hattori M, Sakamoto H, Satoh K, Yamamoto T: DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001, 169(2):155-164.
24. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD: Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 2003, 13(5):319-333.
25. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos JM, Isla A, Sarasa JL, Rey JA: Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2003, 144(2):134-142.
26. Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, De Campos JM, Vaquero J, Isla A, Gutierrez M, Rey JA: Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 2003, 22(3):601-608.
27. Clark SJ, Harrison J, Paul CL, Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994, 22(15): 2990-2997.
28. Agrawal R, Imielinski T, Swami A: Mining association rules between sets of items in large databases. ACM SIGMOD Conference 1993:207-216.
29. Yin H, Blanchard KL: DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms. Blood 2000, 95(1):111-119.
30. Sauter P, Matthias P: Coactivator OBF-1 makes selective contacts with both the POU-specific domain and the POU homeodomain and acts as a molecular clamp on DNA. Mol Cell Biol 1998, 18(12): 397-7409.
31. Chen B, Dias P, Jenkins JJ 3rd, Savell VH, Parham DM: Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas. Am J Pathol 1998, 152(4):1071-1079.
32. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2002, 2(2):103-112.
33. Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB: Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate 2001, 48(4):248-253.
34. Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E, Mori N, Saito H, Kinoshita T: Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002, 100(7):2572-2577.
35. Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M, Kleihues P, Ohgaki H: Methylation of the p73 gene in gliomas. Acta Neuropathol (Berl) 2002, 104(4):357-362.
36. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 20(12):1509-1518.
37. Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. Jama 1995, 273(7):564-570.
38. Neibergs HL, Hein DW, Spratt JS: Genetic profiling of colon cancer. J Surg Oncol 2002, 80(4):204-213.
39. Habuchi T, Luscombe M, Elder PA, Knowles MA: Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 1998, 48(3):277-288.
40. Laux DE, Curran EM, Welshons WV, Lubahn DB, Huang TH: Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas. Breast Cancer Res Treat 1999, 56(1): 5-43.
41. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996, 93(14):7149-7153.
42. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR: Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 2001, 46(3):249-256.
43. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999, 59(10):2307-2312.
44. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, Dahiya R: Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002, 94(5):384-390.
45. Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000, 26(1 ):16-17.
46. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ, Gazdar AF: Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 2002, 62(12 : 382-3386.
47. Muller C, Readhead C, Diederichs S, Idos G, Yang R, Tidow N, Serve H, Berdel WE, Koeffler HP: Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol Cell Biol 2000, 20(9):3316-3329.
48. Ghoshal K, Majumder S, Li Z, Dong X, Jacob ST: Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J Biol Chem 2000, 275(1 : 39-547.
49. Viswanathan M, Tsuchida N, Shanmugam G: Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 2003, 105(1):41-46.
50. Fearon ER: BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism? J Natl Cancer Inst 2000, 92(7):515-517.
51. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409(6817):207-211.
52. Rachmilewitz EA: The role of methylation in CML. Przegl Lek 2000, 57(Suppl 1):25-26.
53. Gonzalez-Gomez P, Bello MJ, Alonso ME, Arjona D, Lomas J, de Campos JM, Isla A, Rey JA: CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer 2003, 88(1):109-114.
54. Fan X, Munoz J, Sanko SG, Castresana JS: PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas. Int J Oncol 2002, 21(3):667-674.
55. Ghimenti C, Fiano V, Chiado-Piat L, Chio A, Cavalla P, Schiffer D: Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. J Neurooncol 2003, 61(2):95-102.
56. Dong S, Pang JC, Hu J, Zhou LF, Ng HK: Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 2002, 98(3):370-375.
57. Loiseau H, Arsaut J, Demotes-Mainard J: p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci Lett 1999, 263(2-3):173-176.
58. Satoh Y, Nakagawachi T, Nakadate H, Kaneko Y, Masaki Z, Mukai T, Soejima H: Significant Reduction of WT1 Gene Expression, Possibly Due to Epigenetic Alteration in Wilms' Tumor. J Biochem (Tokyo 2003, 133(3):303-308.
59. Tomita Y, Bilim V, Hara N, Kasahara T, Takahashi K: Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer 2003, 104(4):400-408.
60. Detjen KM, Murphy D, Welzel M, Farwig K, Wiedenmann B, Rosewicz S: Downregulation of p21(waf/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma. Exp Cell Res 2003, 282(2):78-89.
61. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM: Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon and silencing by hypermethylation. J Biol Chem 2000, 275(41):31805-31812.
62. Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB, Herman JG: Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001, 61(12): 689-4692.
63. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR: Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001, 61(3):827-830.
64. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343(19):1350-1354.
65. Toyooka KO TS, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001, 61(11):4556-4560.
66. Azarschab P, Stembalska A, Loncar MB, Pfister M, Sasiadek MM, Blin N: Epigenetic control of E-cadherin (CDH1) by CpG methylation in metastasising laryngeal cancer. Oncol Rep 2003, 10(2): 01-503.
67. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, Suzuki H, Ito H, Tsukino H, Katoh T, Sugimura Y, Shiraishi T: Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003, 106(3):382-387.
68. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R: Methylation of the RASSF1A gene in human cancers. Biol Chem 2002, 383(6):907-914.
69. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP: Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A 2000, 97(2 :710-715.